Johnson & Johnson
Life Sciences Radar, October 2026 edition. Evidence published up to 5 October 2026; job sites read on 6 October 2026. This brief covers AI in drug discovery, and research labs and data. Every link opens the public source. Covers Johnson & Johnson Innovative Medicine R&D only. MedTech items are excluded because no reviewed source tied them to drug discovery.
Disclosure: Andrew Wyatt, Ortent's principal, was Chief Growth Officer at Sapio Sciences, a lab software company, until April 2026. He has no current relationship with, or financial interest in, Sapio or any other supplier. Software vendors, including Sapio and its competitors, appear in this brief only where public sources name them.
Status: Ortent has reviewed this brief; it has not been independently validated. It sets out what the company and others have published. Search coverage varies by company and is described under Coverage limits, and a count of zero means none was identified, not that nothing happened. It does not predict buying intent or measure operational maturity. For this radar, process and CMC development are grouped with manufacturing and excluded from research labs and data.
Scores
| Theme | Priority (1 to 10) | Delivery (0 to 10) | Stage | Commitments made public, last 12 months | R&D roles open on 6 Oct 2026 |
|---|---|---|---|---|---|
| AI in drug discovery | 5 | 4 | live | 4 | 10 |
| Research labs and data | 1 | none | 0 | 19 |
The scores rest only on what the company itself has published about each theme. Commitments and open roles are observed activity: they show what is being started or staffed now, and they never change a score.
Summary
J&J scores 5 out of 10 for priority and 4 out of 10 for delivery in AI in drug discovery. It names an In Silico Discovery function and says AI is already in use in molecular design, shortening the time from hit to lead, with no adoption metric published. Research labs and data scores 1 for priority, resting on a stated deeper investment in data science, and no eligible delivery disclosure was identified. In the last 12 months four AI discovery commitments were made public, against two the year before: an Isomorphic Labs research collaboration, the AISB Bind federated binding-affinity initiative and two J&J Innovation QuickFire Challenges; none was made public for research labs and data. On 6 October 2026 J&J had 10 AI in drug discovery roles and 19 research labs and data roles open, some counted under both themes, including Biologics Discovery data science and agentic AI posts and chemistry IT systems product managers; AWS is named in use and one posting asks for Benchling experience.
AI in drug discovery
What the company says: Priority 5
says Justin Scheer, Vice President, In Silico Discovery, Innovative Medicine R&D, Johnson & Johnson ... Using our highly sophisticated AI, built on in-house data, we aim to accelerate the delivery of medicines
6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026
Once promising disease targets are identified, Johnson & Johnson is then leveraging AI to help discover molecules that could interact with the target.
6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026
By combining data, AI and machine learning (ML), and advanced computing with our scientific expertise, Johnson & Johnson is setting a new pace for discovering life-changing treatments for patients in need.
Artificial Intelligence - advancing healthcare from New Jersey to the world, 4 Sep 2026
Johnson & Johnson employs nearly 7,000 digital specialists and data scientists around the world.
Artificial Intelligence - advancing healthcare from New Jersey to the world, 4 Sep 2026
What it shows running: Delivery 4, live
Johnson & Johnson is then leveraging AI to help discover molecules that could interact with the target. ... The company is doing this through its own state-of-the-art technologies, as well as in partnership with external collaborators.
6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026
So in molecular design in discovery, it's shortening the time from hit to lead. So we can do things faster.
Johnson & Johnson at Bernstein Strategic Decisions Conference (transcript), 27 May 2026, p. 7
So we have a number of examples of oral medicines that we are getting into humans much faster than we were able to do pre utilizing AI. ... we are clearly using it, and it's already ongoing.
Johnson & Johnson at Bernstein Strategic Decisions Conference (transcript), 27 May 2026, p. 8
the integration of UK Biobank’s multiomic data – spanning the genome, proteome, and phenome – is enabling us to create genetic–protein maps and uncover protein–disease links.
Bridging genomics and drug discovery: what UK Biobank means for R&D, 14 Nov 2025
By applying AI, we can identify promising leads more quickly and optimize them to improve their chances of success in the clinic.
6 ways Johnson & Johnson is using AI to help advance healthcare, 8 Apr 2026
Commitments made public in the last 12 months: 4
- AISB Network AISB Bind federated binding-affinity initiative: Founding partner of AISB Bind, a federated initiative to train a small-molecule binding prediction model. New, announced, 22 Sep 2026. Published by: joint release.
- Isomorphic Labs cross-modality research collaboration: Multi-target, cross-modality research collaboration: Isomorphic does in silico prediction and design, J&J runs assays. New, announced, 20 Jan 2026. Published by: partner only.
- Data & AI Fueling R&D of Tomorrow QuickFire Challenge (Singapore & Beyond): Launches grant challenge for AI/ML approaches with potential to transform drug discovery and research. New, announced, 20 Nov 2025. Published by: company.
- CAT-PD QuickFire Challenge (computational de novo antibody design): Launches global challenge for AI/ML de novo antibody design against hard-to-drug targets, reviewed with NVIDIA. New, announced, 8 Oct 2025. Published by: company.
Commitments made public in the year before: 2
- AISB Network Federated OpenFold3 initiative (Apheris): Founding data contributor to AISB initiative fine-tuning OpenFold3 on proprietary structures in a federated environment. New, announced, 27 Mar 2025. Published by: partner only.
- Ailux Biologics (XtalPi) XtalFold AI platform licence: Non-exclusive licence for Janssen to use the XtalFold AI platform for biologics discovery and engineering. New, announced, 10 Oct 2024. Published by: partner only.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 10
- Senior Principal Scientist, Preclinical Safety & Translational Sciences-Translational Pharmacokinetics/Pharmacodynamics, San Diego, California, United States of America, Spring House, Pennsylvania, United States of America
- Principal Scientist, AI & Autonomous Discovery Systems - Spring House, PA, Spring House, Pennsylvania, United States of America
- Senior Data Scientist, Biologics Discovery, Madrid, Spain, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Principal Agentic Workflow & AI Engineer, Biologics Discovery, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Senior Data Scientist, Biologics Discovery - Madrid, ES, Madrid, Spain
- Senior Machine Learning Engineer, Biologics Discovery, Beerse, Antwerp, Belgium, Madrid, Spain, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Senior Scientist, In Silico Discovery, Beerse, Antwerp, Belgium, La Jolla, California, United States of America, Spring House, Pennsylvania, United States of America
- Principal Scientist - AI-Reasoning for Drug Discovery, Cambridge, Massachusetts, United States of America, New Brunswick, New Jersey, United States of America, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Senior ML Engineer, Biologics Discovery - ES, Madrid, Spain
- Senior ML Engineer, Biologics Discovery - BE, Beerse, Antwerp, Belgium
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Research labs and data
What the company says: Priority 1
Dr. Reed: ... Executive Vice President, Innovative Medicine R&D ... Deepened investment in data science and digital health to accelerate discovery and development across the portfolio.
What it shows running: Delivery none
No company evidence that the work is running was identified in the reviewed sources.
Commitments made public in the last 12 months: 0
None identified in the reviewed sources.
Commitments made public in the year before: 0
None identified in the reviewed sources.
Search coverage for this theme: partial. Commitments count once per initiative, however many announcements they get.
R&D roles open on 6 October 2026: 19
- Principal Scientist, Biologics Optimization, Spring House, Pennsylvania, United States of America
- Technical Product Manager, Chemistry IT Systems, San Diego, California, United States of America, Spring House, Pennsylvania, United States of America
- Associate Director, Expression Sciences, Spring House, Pennsylvania, United States of America
- Technical Product Manager, Chemistry IT Systems (linked requisition), see source posting, posting since closed
- Principal Scientist, AI & Autonomous Discovery Systems - Spring House, PA, Spring House, Pennsylvania, United States of America
- Sr Eng RD Soft Eng, Hyderabad, Andhra Pradesh, India
- Eng RD Soft Eng, Hyderabad, Andhra Pradesh, India
- Principal Agentic Workflow & AI Engineer, Biologics Discovery, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Director, Omics Enabling Platforms, Spring House, Pennsylvania, United States of America
- Principal Data Engineer, Biologics Discovery, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Senior Ontologist, Biologics Discovery, Beerse, Antwerp, Belgium, Madrid, Spain, Raritan, New Jersey, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Principal Developer, Oncology Data & AI Systems (2 available), Cambridge, Massachusetts, United States of America, Raritan, New Jersey, United States of America, San Diego, California, United States of America, Spring House, Pennsylvania, United States of America, Titusville, New Jersey, United States of America
- Senior Ontologist, Biologics Discovery - ES, Madrid, Spain
- Senior Ontologist, Biologics Discovery - BE, Beerse, Antwerp, Belgium
- Head of Technology - Therapeutic Areas (TAs) & External Scientific Innovation (ESI), Cambridge, Massachusetts, United States of America, La Jolla, California, United States of America, Spring House, Pennsylvania, United States of America
- Principal Engineer, AI/Software Support, Pooled Screening Core, Cell & Genetic Medicines, Remote (US), Spring House, Pennsylvania, United States of America
- Head of Technology - Therapeutic Areas (TAs) & External Scientific Innovation (ESI), Beerse, Antwerp, Belgium
- Head of Technology - Therapeutic Areas (TAs) & External Scientific Innovation (ESI), High Wycombe, Buckinghamshire, United Kingdom
- Senior Manager, PSTS, San Diego, California, United States of America, Spring House, Pennsylvania, United States of America
These are postings listed on one day, not hires, headcount or a trend. Roles that serve both themes appear under each.
Technology named in these postings
Named as in use: AWS, AWS services.
Asked for as experience: Benchling.
A product named in a job advert shows what a team wants people to know. It is not proof of a purchase or an installed system.
Two questions to investigate (Ortent's interpretation)
- Lab and scientific data systems for discovery sit with Research Systems, Business Technology, DDSAI and discovery groups such as Biologics Discovery, so who decides on new systems such as LIMS, ELN and lab automation, and how do these units divide the work?
- Who decides whether J&J takes in an external AI model or platform, as with Isomorphic Labs, XtalPi's Ailux and the AISB Network, or builds its own, and does that run through J&J Innovation, In Silico Discovery, DDSAI or procurement?
Coverage limits
www.jnj.com and innovativemedicine.jnj.com served a block page and investor.jnj.com a Cloudflare challenge, so the company newsroom was not read and company releases for some deals may exist unseen. The FY2025 Form 10-K and the results slide decks were not retrieved, so annual report evidence for the last 12 months is partial. Business Wire, GlobeNewswire, Fierce Biotech, Endpoints News and several archive and trade sites also blocked access or failed. Three of the six counted AI commitments were found only through J&J Innovation's own news feed, so other items may have been missed.
Clarity when it counts.
For a board, advisory or fractional engagement, or a working call on the next stage, send a note. Thirty minutes is usually enough to test fit.
Request a 30-minute intro call